Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) closed the day trading at $7.83 up 0.90% from the previous closing price of $7.76. In other words, the price has increased by $0.90 from its previous closing price. On the day, 0.65 million shares were traded. YMAB stock price reached its highest trading level at $7.98 during the session, while it also had its lowest trading level at $7.49.
Ratios:
For a better understanding of YMAB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.54 and its Current Ratio is at 3.92. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on November 18, 2024, initiated with a Outperform rating and assigned the stock a target price of $23.
On August 16, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.
On June 28, 2024, Truist started tracking the stock assigning a Buy rating and target price of $21.Truist initiated its Buy rating on June 28, 2024, with a $21 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 13 ’24 when Gad Thomas sold 65,000 shares for $13.47 per share. The transaction valued at 875,550 led to the insider holds 97,681 shares of the business.
Gad Thomas sold 30,000 shares of YMAB for $389,100 on Sep 16 ’24. The CHIEF BUSINESS OFFICER now owns 67,681 shares after completing the transaction at $12.97 per share. On Sep 13 ’24, another insider, Thomas Gad, who serves as the Officer of the company, bought 100,000 shares for $13.74 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, YMAB now has a Market Capitalization of 350698656 and an Enterprise Value of 283651456. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.19 while its Price-to-Book (P/B) ratio in mrq is 3.79. Its current Enterprise Value per Revenue stands at 3.355 whereas that against EBITDA is -12.147.
Stock Price History:
Over the past 52 weeks, YMAB has reached a high of $20.90, while it has fallen to a 52-week low of $6.48. The 50-Day Moving Average of the stock is -32.70%, while the 200-Day Moving Average is calculated to be -39.37%.
Shares Statistics:
Over the past 3-months, YMAB traded about 265.61K shares per day on average, while over the past 10 days, YMAB traded about 465750 shares per day. A total of 44.77M shares are outstanding, with a floating share count of 37.22M. Insiders hold about 16.91% of the company’s shares, while institutions hold 60.19% stake in the company. Shares short for YMAB as of 1734048000 were 3619213 with a Short Ratio of 13.63, compared to 1731628800 on 3633416. Therefore, it implies a Short% of Shares Outstanding of 3619213 and a Short% of Float of 9.689999.
